TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on November 15, 2013, covering events that occurred on November 14, 2013. The filing addresses a specific amendment to a compensatory arrangement for a senior officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation terms and does not contain financial performance data.
Material Changes
The Board of Directors approved an amendment to the Restricted Stock Subscription Agreement of Sean Power, the Company's Chief Financial Officer. The amendment modifies the repurchase option lapse schedule originally set for November 15, 2013, extending it to January 1, 2015. All other material terms of the agreement remain unchanged.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The document is limited to the disclosure of the executive compensation amendment.
Key Facts for Investor Verification
- Sean Power, Chief Financial Officer, received an amendment to his Restricted Stock Subscription Agreement.
- The repurchase option lapse date was extended from November 15, 2013, to January 1, 2015.
- The original agreement was filed as Exhibit 10.33 to the Company's Form 10-K for the fiscal year ended December 31, 2011.
- The amendment is filed as Exhibit 10.1 to this Form 8-K.